Lyell Immunopharma, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
LYEL Company Description
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
LYEL Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view LYEL Smart Score
Score Breakdown
LYEL Company Description
Show More
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of LYEL by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by LYEL's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of LYEL in WallStreetBets Daily Discussion
LYEL News
Recent insights relating to LYEL
CNBC Recommendations
Recent picks made for LYEL stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in LYEL
Corporate Flights
Flights by private jets registered to LYEL
Our Analysis